Cargando…
Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors
Two series of dimethoxy-halogenated chalcones (DM1–DM20) were synthesized and tested for their ability to inhibit monoamine oxidase (MAOs). Compound DM2 exhibited the most significant inhibition against MAO-B with an IC(50) value of 0.067 µM, followed by compound DM18 (IC(50) = 0.118 µM), with selec...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503132/ https://www.ncbi.nlm.nih.gov/pubmed/36145373 http://dx.doi.org/10.3390/ph15091152 |
_version_ | 1784795887158951936 |
---|---|
author | Rehuman, Nisha Abdul Oh, Jong Min Abdelgawad, Mohamed A. Beshr, Eman A. M. Abourehab, Mohammed A. S. Gambacorta, Nicola Nicolotti, Orazio Jat, Rakesh Kumar Kim, Hoon Mathew, Bijo |
author_facet | Rehuman, Nisha Abdul Oh, Jong Min Abdelgawad, Mohamed A. Beshr, Eman A. M. Abourehab, Mohammed A. S. Gambacorta, Nicola Nicolotti, Orazio Jat, Rakesh Kumar Kim, Hoon Mathew, Bijo |
author_sort | Rehuman, Nisha Abdul |
collection | PubMed |
description | Two series of dimethoxy-halogenated chalcones (DM1–DM20) were synthesized and tested for their ability to inhibit monoamine oxidase (MAOs). Compound DM2 exhibited the most significant inhibition against MAO-B with an IC(50) value of 0.067 µM, followed by compound DM18 (IC(50) = 0.118 µM), with selectivity index (SI) values of 93.88 and >338.98, respectively. However, none of the substances successfully inhibited MAO-A. The MAO-B inhibitors DM2 and DM18 were competitive and reversible, with K(i) values of 0.032 ± 0.004 and 0.045 ± 0.001 µM, respectively. DM2 was non-toxic below 100 µg/mL in the cytotoxic test using the Vero epithelial cell line by the MTT method. According to molecular docking studies, DM2 and DM18 formed very similar conformations within the MAO-B binding pocket, with the ortho-chlorine and ortho-fluorine aromatic rings sandwiched between F168 and Y326. These conformations were predicted to show better interactions with the targeted MAO-B than MAO-A. In particular, the induced-fit docking of the dimethoxy phenyl ring of DM2 facing the hydrophobic pocket made up of FAD, Y398, and Y435 had an impact on F168 in the docking pocket. Taken together, DM2 and DM18 may be suitable candidates for treating neurodegenerative conditions such as Parkinson’s disease. |
format | Online Article Text |
id | pubmed-9503132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95031322022-09-24 Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors Rehuman, Nisha Abdul Oh, Jong Min Abdelgawad, Mohamed A. Beshr, Eman A. M. Abourehab, Mohammed A. S. Gambacorta, Nicola Nicolotti, Orazio Jat, Rakesh Kumar Kim, Hoon Mathew, Bijo Pharmaceuticals (Basel) Article Two series of dimethoxy-halogenated chalcones (DM1–DM20) were synthesized and tested for their ability to inhibit monoamine oxidase (MAOs). Compound DM2 exhibited the most significant inhibition against MAO-B with an IC(50) value of 0.067 µM, followed by compound DM18 (IC(50) = 0.118 µM), with selectivity index (SI) values of 93.88 and >338.98, respectively. However, none of the substances successfully inhibited MAO-A. The MAO-B inhibitors DM2 and DM18 were competitive and reversible, with K(i) values of 0.032 ± 0.004 and 0.045 ± 0.001 µM, respectively. DM2 was non-toxic below 100 µg/mL in the cytotoxic test using the Vero epithelial cell line by the MTT method. According to molecular docking studies, DM2 and DM18 formed very similar conformations within the MAO-B binding pocket, with the ortho-chlorine and ortho-fluorine aromatic rings sandwiched between F168 and Y326. These conformations were predicted to show better interactions with the targeted MAO-B than MAO-A. In particular, the induced-fit docking of the dimethoxy phenyl ring of DM2 facing the hydrophobic pocket made up of FAD, Y398, and Y435 had an impact on F168 in the docking pocket. Taken together, DM2 and DM18 may be suitable candidates for treating neurodegenerative conditions such as Parkinson’s disease. MDPI 2022-09-16 /pmc/articles/PMC9503132/ /pubmed/36145373 http://dx.doi.org/10.3390/ph15091152 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rehuman, Nisha Abdul Oh, Jong Min Abdelgawad, Mohamed A. Beshr, Eman A. M. Abourehab, Mohammed A. S. Gambacorta, Nicola Nicolotti, Orazio Jat, Rakesh Kumar Kim, Hoon Mathew, Bijo Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors |
title | Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors |
title_full | Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors |
title_fullStr | Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors |
title_full_unstemmed | Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors |
title_short | Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors |
title_sort | development of halogenated-chalcones bearing with dimethoxy phenyl head as monoamine oxidase-b inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503132/ https://www.ncbi.nlm.nih.gov/pubmed/36145373 http://dx.doi.org/10.3390/ph15091152 |
work_keys_str_mv | AT rehumannishaabdul developmentofhalogenatedchalconesbearingwithdimethoxyphenylheadasmonoamineoxidasebinhibitors AT ohjongmin developmentofhalogenatedchalconesbearingwithdimethoxyphenylheadasmonoamineoxidasebinhibitors AT abdelgawadmohameda developmentofhalogenatedchalconesbearingwithdimethoxyphenylheadasmonoamineoxidasebinhibitors AT beshremanam developmentofhalogenatedchalconesbearingwithdimethoxyphenylheadasmonoamineoxidasebinhibitors AT abourehabmohammedas developmentofhalogenatedchalconesbearingwithdimethoxyphenylheadasmonoamineoxidasebinhibitors AT gambacortanicola developmentofhalogenatedchalconesbearingwithdimethoxyphenylheadasmonoamineoxidasebinhibitors AT nicolottiorazio developmentofhalogenatedchalconesbearingwithdimethoxyphenylheadasmonoamineoxidasebinhibitors AT jatrakeshkumar developmentofhalogenatedchalconesbearingwithdimethoxyphenylheadasmonoamineoxidasebinhibitors AT kimhoon developmentofhalogenatedchalconesbearingwithdimethoxyphenylheadasmonoamineoxidasebinhibitors AT mathewbijo developmentofhalogenatedchalconesbearingwithdimethoxyphenylheadasmonoamineoxidasebinhibitors |